Overview
- Editors:
-
-
Paul G. Winyard
-
William Harvey Research Institute, London, UK
-
Derek A. Willoughby
-
William Harvey Research Institute, London, UK
Access this book
Other ways to access
Table of contents (36 protocols)
-
-
In Vitro Systems for Studying Aspects of the Inflammatory Response and Testing Antiinflammatory Drugs
-
-
-
-
- Deborah Phippard, Anthony M. Manning
Pages 19-23
-
- Susan L. Cuvelier, Kamala D. Patel
Pages 25-34
-
- M. Rachel Morris, Sharon Dewitt, Iraj Laffafian, Maurice B. Hallett
Pages 35-46
-
- Sharon Dewitt, Iraj Laffafian, M. Rachel Morris, Maurice B. Hallett
Pages 47-59
-
- Maurice B. Hallett, Caroline Cole, Sharon Dewitt
Pages 61-67
-
-
- Linda Troeberg, Hideaki Nagase
Pages 77-87
-
- Clare E. Hughes, Christopher B. Little, Bruce Caterson
Pages 89-98
-
-
In Vivo Models of Inflammation
-
Front Matter
Pages 107-107
-
-
-
-
-
- Mauro Perretti, Stephen J. Getting
Pages 139-146
-
- Nancy L. McCartney-Francis, James Chan, Sharon M. Wahl
Pages 147-159
About this book
Inflammation has been described as the basis of many pathologies of human disease. When one considers the updated signs of inflammation, they would be vasodilation, cell migration, and, in the case of chronic inflam- tion, cell proliferation, often with an underlying autoimmune basis. Gen- ally, inflammation may be divided into acute, chronic, and autoimmune, - though the editors believe that most, if not all, chronic states are often the result of an autoimmune response to an endogenous antigen. Thus, a proper understanding of the inflammatory basis may provide clues to new therap- tic targets not only in classical inflammatory diseases, but atherosclerosis, cancer, and ischemic heart disease as well. The lack of advances in classical inflammatory diseases, such as rh- matoid arthritis, may in part arise from a failure to classify the disease into different forms. That different forms exist is exemplified in patients with d- fering responses to existing antiinflammatory drugs, ranging from nonresponders to very positive responders for a particular nonsteroidal an- inflammatory drug (NSAID). Though researchers have progressively unr- eled the mechanisms, the story is far from complete. It should also be noted that the inflammatory response is part of the innate immune response, or to use John Hunter’s words in 1795, “inflammation is a salutary response.” That may be applied in particular to the defensive response to invading micro- ganisms.
